Susquehanna International Group, LLP Akebia Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$0.86 - $1.63 $226,696 - $429,668	-263,600 Reduced 37.92%	431,600 $440,000
Q1 2024 May 07, 2024	BUY	$1.27 - $2.24 $690,880 - $1.22 Million	544,000 Added 359.79%	695,200 $1.27 Million
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $1,040 - $1,664	1,300 Added 0.87%	151,200 $187,000
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.84 $23,838 - $50,416	27,400 Added 22.37%	149,900 $170,000
Q2 2023 Aug 11, 2023	SELL	$0.51 - $1.43 $6,120 - $17,160	-12,000 Reduced 8.92%	122,500 $112,000
Q1 2023 May 16, 2023	BUY	$0.56 - $1.15 $40,656 - $83,490	72,600 Added 117.29%	134,500 $75,000
Q4 2022 Feb 14, 2023	SELL	$0.25 - $0.58 $5,125 - $11,890	-20,500 Reduced 24.88%	61,900 $35,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $2,670 - $4,094	-8,900 Reduced 9.75%	82,400 $26,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $73,024 - $152,894	-228,200 Reduced 71.42%	91,300 $32,000
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $190,800 - $776,450	265,000 Added 486.24%	319,500 $230,000
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $170,177 - $251,502	-75,300 Reduced 58.01%	54,500 $123,000
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $241,815 - $399,252	-102,900 Reduced 44.22%	129,800 $374,000
Q2 2021 Aug 11, 2021	BUY	$2.83 - $4.2 $120,558 - $178,920	42,600 Added 22.41%	232,700 $882,000
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $91,396 - $158,378	31,300 Added 19.71%	190,100 $643,000
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $522,144 - $889,056	-235,200 Reduced 59.7%	158,800 $445,000
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $312,612 - $1.71 Million	-130,800 Reduced 24.92%	394,000 $989,000
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $2.25 Million - $4.58 Million	337,000 Added 179.45%	524,800 $7.13 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $514,959 - $1.29 Million	125,600 Added 201.93%	187,800 $1.42 Million
Q4 2019 Feb 14, 2020	SELL	$3.16 - $6.73 $56,248 - $119,794	-17,800 Reduced 22.25%	62,200 $393,000
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $89,815 - $136,620	-25,300 Reduced 24.03%	80,000 $314,000
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $469,449 - $921,725	-114,500 Reduced 52.09%	105,300 $510,000
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $43,280 - $69,840	-8,000 Reduced 3.51%	219,800 $1.8 Million
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $993,915 - $1.69 Million	184,400 Added 424.88%	227,800 $1.26 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $146,568 - $209,805	19,700 Added 83.12%	43,400 $383,000
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $34,770 - $43,092	3,800 Added 19.1%	23,700 $237,000
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $259,894 - $391,433	19,900	19,900 $391,000

Others Institutions Holding AKBA

# of Institutions

110

Shares Held

55.3M

Call Options Held

554K

Put Options Held

246K

Black Rock Inc. New York, NY

11.6M
Shares

$15.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

9.28M
Shares

$12.3 Million
0.0% of portfolio
Satter Management Co., L.P.

5.75M
Shares

$7.64 Million
11.5% of portfolio
Geode Capital Management, LLC Boston, MA

4.54M
Shares

$6.03 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

4.06M
Shares

$5.4 Million
0.01% of portfolio

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $245M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account